Search Results
Your search for ,amp matches 4215 pages
Showing 451 - 500Durvalumab Consolidation Therapy Extends Survival in Limited-Stage Small Cell Lung Cancer
Consolidation therapy with the PD-L1 antibody durvalumab after chemoradiotherapy extended survival in patients with limited-stage small cell lung cancer (SCLC) compared with standard-of-care chemoradiotherapy alone, according to the first planned interim analysis of the phase III ADRIATIC trial...
Study Finds Fewer Than Half of Accelerated Approval Drugs Show Benefit in Overall Survival or Quality of Life Within 5 Years
In 1992, the U.S. Food and Drug Administration (FDA) instituted the Accelerated Approval regulations, which allow drugs that treat serious conditions, including cancer, and fill an unmet need to be approved early based on a surrogate endpoint.1 However, any drug approved under this pathway is still ...
Pembrolizumab/Chemotherapy in First-Line Treatment of HER2-Negative Advanced Gastric or GEJ Adenocarcinoma
On November 16, 2023, pembrolizumab (Keytruda) was approved with fluoropyrimidine- and platinum-containing chemotherapy for first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.1 Supporting Efficacy Data Approval ...
LGBTQ+ Cancer Survivors Have a Higher Burden of Chronic Health Conditions, Disabilities Than Non-LGBTQ+ Cancer Survivors
Although improvements in the early detection and treatment of cancer have reduced cancer-related mortality rates and increased the number of cancer survivors in the United States to over 18 million, not all patients with the disease are benefiting from these advances. A recent study investigated...
Updated ASTRO Clinical Guidelines on Radiation Therapy for HPV-Positive Oropharyngeal Cancer
The American Society for Radiation Oncology (ASTRO) detailed best practices for using radiation therapy as a stand-alone curative treatment or in combination with surgery and/or chemotherapy to treat patients with human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma,...
Previously Treated Metastatic Colorectal Cancer: Lenvatinib/Pembrolizumab vs Standard of Care
As reported in the Journal of Clinical Oncology by Akihito Kawazoe, MD, and colleagues, the final analysis of the phase III LEAP-017 trial showed no significant overall survival benefit with lenvatinib plus pembrolizumab vs the standard of care in previously treated patients with mismatch...
Study Documents Decline in Reimbursements for Breast Cancer Surgery From 2003 to 2023
Over the past 20 years, Medicare reimbursements for 10 breast cancer surgical procedures rose by 22%, but inflation rose three times as much—by 69%. Compared with the financial picture had rates kept pace with inflation, the result is an estimated aggregate loss of more than $100 million for breast ...
Mobile Monitoring System May Improve Detection of Ethylene Oxide in Louisiana’s ‘Cancer Alley’
Measuring ethylene oxide levels using mobile optical instruments in Louisiana’s southeastern corridor may help to improve cancer risk assessments, according to a recent study published by Robinson et al in Environmental Science & Technology. Background Louisiana’s southeastern corridor is...
Relapsed or Refractory JMML: Study Evaluates Trametinib
Juvenile myelomonocytic leukemia (JMML) is a rare and aggressive hematologic malignancy affecting young children predominately under the age of 4. The disease is caused by mutations that increase RAS signaling output. While about 50% of patients with JMML are cured after undergoing hematopoietic...
Lung Cancer Screening Prevalence Among Eligible U.S. Individuals
In a study reported in JAMA Internal Medicine, Bandi et al found that only 18% of eligible individuals in the United States were considered up to date—defined as undergoing screening within the past year—for recommended annual lung cancer screening in 2022. As stated by the investigators, “The U.S. ...
Multiple Myeloma Survivor and Advocate Shares 12-Step Program: How Not to Die of Cancer
Facing mortality can be a paralyzing experience for some people, but for others, it may ignite a passion to accelerate life. One such person is Kathy Giusti, cofounder of the Multiple Myeloma Research Foundation (MMRF), where she served as Chief Executive Officer and President for nearly 20 years....
LEAP-001: Study Misses Endpoints but Still Shows Benefit for Lenvatinib/Pembrolizumab in Endometrial Cancer Subsets
The highly anticipated ENGOT-en9/LEAP-001 trial in endometrial cancer has missed both its primary endpoints. At the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer, the study investigators reported no significant benefit in progression-free survival or overall survival...
Study Finds Early Menopause May Be Linked to Greater Risk of Breast and Ovarian Cancers
The risk of breast cancer and ovarian cancer may be increased in some women who experience early menopause, according to new findings presented by Welt et al at the Endocrine Society’s Annual Meeting & Exposition 2024. Primary ovarian insufficiency is a condition that occurs when a woman’s...
Impact of High Blood Insulin Levels on Triple-Negative Breast Cancer Survival in Black Women
High blood insulin levels may contribute to worse outcomes in Black women with triple-negative breast cancer compared with White women with the disease, according to new findings presented by Engel et al at the Endocrine Society’s Annual Meeting & Exposition 2024. Background Triple-negative...
Stress Related to Residing in Violent Neighborhoods May Be Tied to Aggressive Lung Cancer in Black Men
Exposure to increased neighborhood violence may change the glucocorticoid receptor for the stress hormone cortisol and influence the aggressiveness of lung cancer, according to new findings presented by Heath et al at the Endocrine Society’s Annual Meeting & Exposition 2024. Study Methods and...
Many Breast Cancer Survivors May Experience Excess Weight Gain
Nearly 20% of breast cancer survivors may experience weight gain of more than 10%, according to recent findings presented by Hurtado Andrade et al at the Endocrine Society’s Annual Meeting & Exposition 2024. The research may illuminate a number of factors potentially contributing to excessive...
Novel Antibody-Drug Conjugate May Improve Response in Advanced Colorectal Cancer
The antibody-drug conjugate M9140 exhibited activity in pretreated patients with advanced colorectal cancer, according to preliminary data from a phase I study presented by Kopetz et al at the 2024 ASCO Annual Meeting (Abstract 3000). Background M9140 is one of the first antibody-drug conjugates...
Belinda Lee, MBBS, on Early-Stage Pancreatic Cancer: New Data on Guiding Adjuvant Chemotherapy
Belinda Lee, MBBS, of Peter MacCallum Cancer Centre, Northern Health, Walter & Eliza Hall Institute, Melbourne, discusses findings from the AGITG DYNAMIC-Pancreas trial on the potential role of serial circulating tumor DNA testing after upfront surgery to guide adjuvant chemotherapy for...
Telehealth Shown to Be Effective for Palliative Care Delivery in Patients With Advanced Lung Cancer
New research reinforces the telehealth delivery of palliative care as an effective alternative to in-person visits for patients with advanced lung cancer, providing comparable quality-of-life benefits. This research was presented by Joseph Greer, PhD, and colleagues at the 2024 ASCO Annual Meeting...
A Father’s Advice Plus a Desire to Help Spur a Career in Oncology and a Leadership Role in African Cancer Care
Miriam Mutebi, MD, MSc, FACS, was born and reared in the outskirts of Nairobi, Kenya. “The suburb I grew up in (Langata), has seen a lot of development over the past couple of decades. When I was a child, it was a smaller community, where you would go and play at somebody else’s house and have...
For an International Expert in Gynecologic Cancer, Being Reared by Educators Who Stressed Knowledge and Service Was Key
Deputy Editor of The ASCO Post, Jame Abraham, MD, FACP, recently spoke with gynecologic cancer expert Sharmila K. Makhija, MD, MBA, about her journey to her current position as Founding Dean and Chief Executive Officer of the Alice L. Walton School of Medicine, Bentonville, Arkansas. Raised by...
Cancer Incidence, Curative Treatment, and Overall Survival in the English Prison Population
In a study reported in The Lancet Oncology, Lüchtenborg et al found that the incidence of cancer increased in the prison population in England between 1998 and 2017; those with cancer were less likely to receive curative treatment and had poorer overall survival vs patients with cancer in the...
Applying the Power of Knowledge to Drive Positive Change in Oncology Care
An ASCO volunteer for nearly 30 years, Robin T. Zon, MD, FACP, FASCO, is humbled and honored to be elected ASCO’s 61st President, effective during the 2024 ASCO Annual Meeting, May 31 to June 4, 2024, in Chicago and online. Dr. Zon began her 4-year term in June 2023 as President-Elect and will...
We Have an IDEA: United in the Fight Against Cancer
On behalf of 2024 International Development and Education Award (IDEA) awardees, we received the decision of our acceptance in this outstanding training program offering mentorship and educational opportunities for early-career oncologists and cancer researchers with great interest. This will...
Partnering With Patients Is Integral for a Good Outcome
About 3 years ago, I woke up from a sound sleep and was having a hard time breathing. It felt like someone was sitting on my neck, constricting my airways. I could feel prominent swelling in my lymph nodes along my neck and clavicle, and I was scared. A trip to the emergency room proved fruitless, ...
Understanding the Legal and Ethical Challenges AI Poses in Oncology
The field of oncology is experiencing a revolution driven by artificial intelligence (AI) technology. Artificial intelligence tools are already being used in medical imaging analysis, treatment planning, and even patient counseling. These advancements hold immense promise for earlier cancer...
Pembrolizumab in High-Risk Non–Muscle-Invasive Bladder Cancer
As reported in The Lancet Oncology by Andrea Necchi, MD, and colleagues, findings in cohort B of the phase II KEYNOTE-057 study indicated that pembrolizumab was active in patients with bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non–muscle invasive bladder cancer. As noted by the...
HPV Screening Intervals for Cervical Cancer May Be Safely Extended Beyond Current 5-Year Recommendation, Study Finds
A longitudinal cohort study published by Gottschlich et al in Cancer Epidemiology, Biomarkers & Prevention investigated the optimal interval between screening tests and the long-term risk of cervical precancer or worse (CIN2+). Researchers found that the risk of cervical precancer 8 years after ...
Previously Untreated Mantle Cell Lymphoma: Ibrutinib, Immunochemotherapy, and ASCT
As reported in The Lancet by Martin Dreyling, MD, PhD, and colleagues, results in the European Mantle Cell Lymphoma Network phase III TRIANGLE trial indicate that the addition of ibrutinib to immunochemotherapy and autologous stem cell transplantation (ASCT) significantly improved failure-free...
Pembrolizumab/Chemotherapy for Advanced Biliary Tract Cancer
On October 31, 2023, pembrolizumab (Keytruda) was approved for use with gemcitabine/cisplatin in first-line treatment of patients with locally advanced unresectable or metastatic biliary tract cancer.1 Supporting Efficacy Data Approval was based on the double-blind KEYNOTE-966 trial...
Belzutifan in Previously Treated Advanced Renal Cell Carcinoma
On December 14, 2023, the hypoxia-inducible factor inhibitor belzutifan (Welireg) was approved for patients with unresectable locally advanced or metastatic clear cell renal cell carcinoma with disease progression on previous treatment with a PD-1 or PD-L1 inhibitor and a vascular endothelial...
Enfortumab Vedotin-ejfv Plus Pembrolizumab Improves Survival vs Platinum-Based Chemotherapy in Advanced Urothelial Cancer
As reported in The New England Journal of Medicine by Thomas Powles, MD, Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, and colleagues, the phase III EV-302 trial has shown that the combination of the antibody–drug conjugate enfortumab vedotin-ejfv, which is...
DUO-E Trial: Results Support New Treatment Options in Endometrial Cancer
New research findings have highlighted the importance of personalized treatment approaches with the monoclonal antibody durvalumab based on mismatch repair (MMR) status in newly diagnosed patients with advanced or recurrent endometrial cancer, according to data presented during the Society of...
Bispecific Antibody Plus Chemotherapy Improves Survival in Patients With Gastric or Gastroesophageal Junction Cancer
Treatment with the first-in-class PD-1/CTLA-4 bispecific antibody cadonilimab plus XELOX (capecitabine, oxaliplatin) chemotherapy demonstrated a survival advantage for patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma as first-line treatment, regardless of PD-L1...
Two Studies Support Deintensification of Treatment for HPV-Associated Oropharyngeal Cancer
Two studies presented at the 2024 Multidisciplinary Head and Neck Cancers Symposium added support for the deintensification of radiotherapy in early-stage oropharyngeal squamous cell cancers associated with the human papillomavirus (HPV), a subtype typically more responsive to therapy compared to...
For Detection of Measurable Residual Disease in Ovarian Cancer, Are Two Methods Better Than One?
In patients with ovarian cancer, second-look surgery may find a role again. The evaluation of measurable residual disease (MRD) using second-look laparoscopy identified more women who had detectable MRD after front-line treatment than did circulating tumor DNA (ctDNA), according to a study...
Preferred Sites of Cancer Care: Community Oncology Practices vs Hospitals and Academic Centers
Investigators uncovered that community oncology practices emerged as the preferred sites of service for cancer treatment compared with hospitals and academic centers, according to a recent case study. The findings may challenge the common perception of hospitals and academic centers as preferable...
Mortality Trends Among Asian American, Native Hawaiian, and Other Pacific Islander Patients With Preventable Cancers
The American Cancer Society (ACS) has detailed disparities in the mortality rates for preventable cancer types among Asian American, Native Hawaiian, and other Pacific Islander patients in a new Cancer Facts & Figures report published by Wagle et al. Background In this report, the Asian...
Metastatic Castration-Resistant Prostate Cancer: Addition of LuPSMA to Enzalutamide
In an interim analysis of the Australian phase II ENZA-p trial reported in The Lancet Oncology, Emmett et al found that the addition of lutetium-177–labeled PSMA-617 (LuPSMA) to enzalutamide improved prostate-specific antigen (PSA) progression-free survival in the first-line treatment of patients...
Barriers to Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
Investigators have uncovered persistent racial and social disparities that may impede access to autologous hematopoietic cell transplantation for some patients with multiple myeloma, according to a recent study published by Esteghamat et al in Clinical Lymphoma, Myeloma & Leukemia. Background...
Expert Point of View: Glenn J. Hanna, MD
Glenn J. Hanna, MD, Director, Center for Cancer Therapeutic Innovation (Early Drug Development Program), medical oncologist at the Center for Head & Neck Oncology at Dana-Farber Cancer Institute, and Associate Professor of Medicine, Harvard Medical School, Boston, was interviewed for his...
Adagrasib Plus Cetuximab: Potential Option for KRAS G12C–Mutated Colorectal Cancer
Although KRAS was once considered an untargetable mutation, KRAS inhibitors are now approved for the treatment of KRAS-mutated non–small cell lung cancer (NSCLC) and are emerging as a potential option for the treatment of KRAS G12C–mutated colorectal cancer in combination with other therapies....
Advanced-Stage Classical Hodgkin Lymphoma
Classical Hodgkin lymphoma (HL) is a highly curable disease, but up to 25% of patients will develop relapsed or refractory classical HL. Although most patients achieve complete response following front-line therapy, key unmet clinical needs include reducing the relapse rate, decreasing acute and...
Professional Societies Introduce New Evidence-Based Guidelines on Testing Immunotherapy Biomarkers in NSCLC
The College of American Pathologists in collaboration with the International Association for the Study of Lung Cancer, the Pulmonary Pathology Society, the Association for Molecular Pathology, and the LUNGevity Foundation have developed evidence-based recommendations on the use of certain...
Study Identifies Genetic Variants Potentially Linked to Prevalent or Persistent HPV Infections
Investigators have uncovered genetic variants that may predispose certain female patients to prevalent or persistent human papillomavirus (HPV) infections and increase their risk of developing cervical cancer, according to a recent study published by Adebamowo et al in the European Journal of Human ...
Newly Diagnosed Locally Advanced HNSCC: Adding Pembrolizumab to Concurrent Chemoradiotherapy
As reported in The Lancet Oncology by Jean-Pascal Machiels, MD, and colleagues, the phase III KEYNOTE-412 trial showed no significant improvement in event-free survival with the addition of pembrolizumab to concurrent chemoradiotherapy in newly diagnosed patients with high-risk locally advanced...
The Lancet Commission on Prostate Cancer: Strategies to Prepare for Predicted Increases in Disease Burden by 2040
Investigators have projected impending increases in the incidence and mortality rates of prostate cancer—especially among individuals in low- and middle-income countries—and proposed new strategies to improve screening, awareness, research diversification, and treatment in a recent The Lancet...
BAP1 Mutations May Increase Susceptibility to Asbestos-Induced Malignant Mesothelioma
Researchers have shown that even minimal exposure to chrysotile asbestos may increase susceptibility to the development of malignant mesothelioma in mice with BAP1 germline mutations, according to new findings presented by Kadariya et al at the American Association for Cancer Research (AACR) Annual ...
AACR Inaugurates New Leadership
The members of the American Association for Cancer Research (AACR) elected a new 2024 to 2025 President and President-Elect at the AACR’s Annual Business Meeting of Members during the AACR Annual Meeting 2024 in San Diego. New President The AACR welcomed Patricia M. LoRusso, DO, PhD (hc), FAACR, as ...
Bispecific Immune Checkpoint Inhibitor Improves Survival in Patients With Gastric Cancer, Regardless of PD-L1 Status
The PD-1/CTLA-4 bispecific antibody cadonilimab plus chemotherapy improved progression-free and overall survival in patients with untreated, HER2-negative, locally advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer—including those with PD-L1–low tumors—compared with...
